Is CRVO or ACOG more profitable?

CervoMed has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed N/A -156.02% -128.34% Alpha Cognition -153.61% -54.60% -43.47%

Does the media prefer CRVO or ACOG?

In the previous week, Alpha Cognition had 1 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Alpha Cognition and 4 mentions for CervoMed. Alpha Cognition's average media sentiment score of 0.59 beat CervoMed's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or CRVO more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% CervoMed N/A -156.02% -128.34%

Does the media favor ZNTL or CRVO?

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 4 mentions for CervoMed. Zentalis Pharmaceuticals' average media sentiment score of 0.33 beat CervoMed's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CRVO or ANTX?

CervoMed has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 12.14 -$26.97M -$3.22 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is CRVO or ANTX more profitable?

Anthem's return on equity of -53.52% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed N/A -156.02% -128.34% Anthem N/A -53.52% -48.63%

Is CRVO or DERM more profitable?

CervoMed has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed N/A -156.02% -128.34% Journey Medical -8.95% -20.23% -6.60%

Does the media refer more to CRVO or DERM?

In the previous week, CervoMed had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.42 beat CervoMed's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRVO or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed N/A -156.02% -128.34% Minerva Neurosciences N/A N/A -31.72%

Does the media favor CRVO or NERV?

In the previous week, CervoMed had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.61 beat CervoMed's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CervoMed (CRVO) Competitors

$3.22 -0.06 (-1.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.25 +0.03 (+1.02%)

As of 10/9/2026 07:55 PM Eastern

Compare

CRVO vs. ACOG, ZNTL, ANTX, DERM, and NERV

Should you buy CervoMed stock or one of its competitors? CervoMed's main competitors and comparable companies include Alpha Cognition (ACOG), Zentalis Pharmaceuticals (ZNTL), Anthem (ANTX), Journey Medical (DERM), and Minerva Neurosciences (NERV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CervoMed compare to Alpha Cognition?

CervoMed (NASDAQ:CRVO) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

In the previous week, Alpha Cognition had 1 more articles in the media than CervoMed. MarketBeat recorded 5 mentions for Alpha Cognition and 4 mentions for CervoMed. Alpha Cognition's average media sentiment score of 0.59 beat CervoMed's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed currently has a consensus price target of $21.00, suggesting a potential upside of 552.17%. Alpha Cognition has a consensus price target of $18.00, suggesting a potential upside of 99.12%. Given CervoMed's higher probable upside, equities research analysts clearly believe CervoMed is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

25.2% of CervoMed shares are owned by institutional investors. 35.8% of CervoMed shares are owned by company insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CervoMed has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market.

CervoMed has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	N/A	-156.02%	-128.34%
Alpha Cognition	-153.61%	-54.60%	-43.47%

Alpha Cognition has higher revenue and earnings than CervoMed. Alpha Cognition is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A
Alpha Cognition	$15.26M	12.90	-$20.67M	-$1.10	N/A

Summary

Alpha Cognition beats CervoMed on 11 of the 17 factors compared between the two stocks.

How does CervoMed compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Zentalis Pharmaceuticals currently has a consensus price target of $7.50, indicating a potential upside of 184.09%. CervoMed has a consensus price target of $21.00, indicating a potential upside of 552.17%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

CervoMed has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.81	-$137.06M	-$1.95	N/A
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A

25.2% of CervoMed shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Zentalis Pharmaceuticals' return on equity of -70.18% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
CervoMed	N/A	-156.02%	-128.34%

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 4 mentions for CervoMed. Zentalis Pharmaceuticals' average media sentiment score of 0.33 beat CervoMed's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zentalis Pharmaceuticals and CervoMed tied by winning 8 of the 16 factors compared between the two stocks.

How does CervoMed compare to Anthem?

CervoMed (NASDAQ:CRVO) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, CervoMed had 3 more articles in the media than Anthem. MarketBeat recorded 4 mentions for CervoMed and 1 mentions for Anthem. CervoMed's average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
Anthem	Neutral

CervoMed presently has a consensus price target of $21.00, suggesting a potential upside of 552.17%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 104.55%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts plainly believe CervoMed is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Anthem's return on equity of -53.52% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	N/A	-156.02%	-128.34%
Anthem	N/A	-53.52%	-48.63%

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 35.8% of CervoMed shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CervoMed has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market.

CervoMed has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Summary

CervoMed beats Anthem on 10 of the 14 factors compared between the two stocks.

How does CervoMed compare to Journey Medical?

CervoMed (NASDAQ:CRVO) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

CervoMed currently has a consensus target price of $21.00, indicating a potential upside of 552.17%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 121.87%. Given CervoMed's stronger consensus rating and higher possible upside, equities analysts plainly believe CervoMed is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

25.2% of CervoMed shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, CervoMed had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.42 beat CervoMed's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CervoMed has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Journey Medical has higher revenue and earnings than CervoMed. Journey Medical is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A
Journey Medical	$61.86M	2.88	-$11.43M	-$0.22	N/A

CervoMed has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	N/A	-156.02%	-128.34%
Journey Medical	-8.95%	-20.23%	-6.60%

Summary

CervoMed beats Journey Medical on 10 of the 17 factors compared between the two stocks.

How does CervoMed compare to Minerva Neurosciences?

CervoMed (NASDAQ:CRVO) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

CervoMed currently has a consensus target price of $21.00, indicating a potential upside of 552.17%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 224.95%. Given CervoMed's stronger consensus rating and higher probable upside, equities research analysts plainly believe CervoMed is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

CervoMed has higher revenue and earnings than Minerva Neurosciences. CervoMed is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	12.14	-$26.97M	-$3.22	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

In the previous week, CervoMed had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for CervoMed and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.61 beat CervoMed's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.2% of CervoMed shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CervoMed has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	N/A	-156.02%	-128.34%
Minerva Neurosciences	N/A	N/A	-31.72%

Summary

CervoMed beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.59M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-1.00	797.58	274.15	26.16
Price / Sales	12.14	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.63	10.71	11.21	6.34
Net Income	-$26.97M	$2.84B	$3.50B	$381.90M
7 Day Performance	6.62%	-0.93%	-0.90%	-1.41%
1 Month Performance	29.84%	-4.91%	-4.44%	-3.48%
1 Year Performance	-60.49%	-4.13%	6.96%	1.16%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	2.1487 of 5 stars	$3.22 -1.8%	$21.00 +552.2%	-62.3%	$49.59M	$4.01M	N/A	15
ACOG Alpha Cognition	3.8895 of 5 stars	$8.98 -1.9%	$18.00 +100.4%	+19.4%	$195.58M	$10.22M	N/A	71	News Coverage Short Interest Increase
ZNTL Zentalis Pharmaceuticals	3.3745 of 5 stars	$2.67 -4.0%	$7.50 +180.9%	+45.9%	$191.36M	N/A	N/A	106	Gap Up
ANTX Anthem	1.7204 of 5 stars	$5.07 -9.6%	$9.00 +77.5%	+254.8%	$191.34M	N/A	N/A	N/A
DERM Journey Medical	1.7248 of 5 stars	$6.16 -7.9%	$14.00 +127.3%	-16.4%	$173.86M	$68.18M	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. ACOG, ZNTL, ANTX, DERM, and NERV

How does CervoMed compare to Alpha Cognition?

Summary

How does CervoMed compare to Zentalis Pharmaceuticals?

Summary

How does CervoMed compare to Anthem?

Summary

How does CervoMed compare to Journey Medical?

Summary

How does CervoMed compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. ACOG, ZNTL, ANTX, DERM, and NERV

How does CervoMed compare to Alpha Cognition?

Does the media prefer CRVO or ACOG?

Do analysts recommend CRVO or ACOG?

Do insiders and institutionals hold more shares of CRVO or ACOG?

Which has more volatility & risk, CRVO or ACOG?

Is CRVO or ACOG more profitable?

Which has preferable earnings & valuation, CRVO or ACOG?

Summary

How does CervoMed compare to Zentalis Pharmaceuticals?

Do analysts rate ZNTL or CRVO?

Which has higher earnings and valuation, ZNTL or CRVO?

Do insiders & institutionals believe in ZNTL or CRVO?

Which has more volatility & risk, ZNTL or CRVO?

Is ZNTL or CRVO more profitable?

Does the media favor ZNTL or CRVO?

Summary

How does CervoMed compare to Anthem?

Does the media favor CRVO or ANTX?

Do analysts rate CRVO or ANTX?

Is CRVO or ANTX more profitable?

Do insiders & institutionals have more ownership in CRVO or ANTX?

Which has more volatility & risk, CRVO or ANTX?

Which has preferable earnings & valuation, CRVO or ANTX?

Summary

How does CervoMed compare to Journey Medical?

Do analysts prefer CRVO or DERM?

Do insiders and institutionals hold more shares of CRVO or DERM?

Does the media refer more to CRVO or DERM?

Which has more risk & volatility, CRVO or DERM?

Which has higher valuation and earnings, CRVO or DERM?

Is CRVO or DERM more profitable?

Summary

How does CervoMed compare to Minerva Neurosciences?

Do analysts rate CRVO or NERV?

Which has stronger earnings & valuation, CRVO or NERV?

Does the media favor CRVO or NERV?

Do insiders & institutionals believe in CRVO or NERV?

Which has more risk and volatility, CRVO or NERV?

Is CRVO or NERV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools